Corvus Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
CRVS Corvus Pharmaceuticals Inc
BAC Bank of America Corp
NIO NIO Inc
IO ION Geophysical Corp
PRU Prudential Financial Inc
HAWEM Hawaiian Electric Company Inc
CCFN CCFNB Bancorp Inc
WYNN Wynn Resorts Ltd
WST West Pharmaceutical Services Inc
OSIS OSI Systems Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.

Closing Price
$3.48
Day's Change
-0.10 (-2.79%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.69
Day's Low
3.31
Volume
(Light)
Volume:
1,746,270

10-day average volume:
2,728,299
1,746,270
  • Prev Close
    3.58
  • Today's Open
    3.58
  • Day's Range
    3.31-3.69
  • Avg Vol (10-day)
    2.7M
  • Last (time)
    4:00p ET 02/26/21
  • Last (size)
    436
  • 52-Wk Range
    1.01 - 6.88
    LowHigh
  • (03/16/20 - 07/07/20)
    244.55%
  • 112.7%
  • Market Cap
    131.7M
  • Shares Outstanding
    37.8M
  • -1.51
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 1.8
  • 49.66
  • (% of float 02/15/21)
    3.87

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.